EMA consults on regulatory acceptance of "3R" alternatives to animal studies
This article was originally published in SRA
The European Medicines Agency is seeking stakeholder feedback concerning the revision of its position on the replacement of animal studies with alternative models for drug testing1,2. The exercise, it is expected, will lead to the development of a clear process for the regulatory acceptance of all "3R" (replacement, reduction and refinement) alternative methods for non-clinical testing of medicinal products.
You may also be interested in...
As companies undergo pharmacovigilance inspections from a growing multitude of regulatory authorities from around the globe, a senior pharmaceutical industry executive discusses how her company has been handling this complex and challenging task.
While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.
The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.